Oncozenge AB Cash Flow Conversion Efficiency
Oncozenge AB cash flow conversion efficiency. Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of 12.336x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.24 Million ≈ $-779.25K USD) by net assets (Skr-587.00K ≈ $-63.17K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncozenge AB (2020–2025)
Cash flow conversion efficiency of Oncozenge AB from 2020 to 2025. This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Oncozenge AB stock price today for real-time trading data and today's change.
Oncozenge AB Cash Flow Conversion Ratio Explained
Oncozenge AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency. Also see ONCOZ market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIRD RIVER RES. INC.
F:1Q1A
|
N/A |
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
-0.018x |
|
Sinergi Inti Plastindo
JK:ESIP
|
0.003x |
|
Beowulf Mining PLC
ST:BEO-SDB
|
N/A |
|
Tinybeans Group Ltd
AU:TNY
|
-0.191x |
|
Azucar Minerals Ltd
V:AMZ
|
-0.360x |
|
Dunedin Income Growth Investment Trust PLC
LSE:DIG
|
0.016x |
|
TANTALEX LITHIUM RES.CORP
F:DW8
|
0.067x |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2025. Review how much free cash does Oncozenge AB generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-587.00K ≈ $-63.17K |
Skr-13.06 Million ≈ $-1.41 Million |
22.244x | +2625.38% |
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
Skr-8.76 Million ≈ $-943.15K |
-0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
Skr-17.08 Million ≈ $-1.84 Million |
-0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
Skr-22.08 Million ≈ $-2.38 Million |
-0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
Skr-4.77 Million ≈ $-513.01K |
-0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
Skr-1.00K ≈ $-107.62 |
0.000x | -- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.